China Healthcare Weekly (Mar.2) - NewCo Model, Pfizer-Summit Deal, Henlius to Enter HK Stock Connect
The NewCo model is just an "intermediate state" for Chinese Biotech. After Pfizer-Summit deal, the possibility of Summit being acquired is reduced....
739 Views
APAC Healthcare Weekly (Mar 2)- Celltrion, Samsung Biologics, Biocon, Zydus Life, Healthcare Global
APAC healthcare companies continued to get approvals for new products and initiates clinical trials. The companies continued with acquisitions and...
624 Views
Xtapli Placement - Questionable Timing. An AI Momentum Play, at Best
Xtapli is looking to raise around US$242m via a primary placement, after having raised US$145m in Jan 2025. In this note, we talk about the deal...
570 Views
Hengrui (ęēå»čÆ) A/H Listing: A Worthy Comparison with Hansoh Pharma
āChina's Jiangsu Hengrui Medicine plans to raise $2bn in H-share listing. We did a worthy comparison between it and Hansoh Pharma.
643 Views
Jiangsu Hengrui Pharma A/H Listing - Innovation and Overseas Expansion Driving Earnings Rebound
Jiangsu Hengrui Medicine (600276 CH) a China-based pharmaceutical company, aims to raise around US$2bn in its H-share listing.
527 Views